
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV exhibits a strong financial outlook driven by a significant increase in management confidence regarding the efficacy of AMT-130 for Huntington's disease, supported by robust data and broad scientific endorsement. While SG&A expenses have risen to $19.4 million from $11.6 million year-over-year, the absence of new regulatory concerns surrounding manufacturing and safety enhances the risk-benefit profile of its therapies. Furthermore, the positive Independent Data Monitoring Committee (IDMC) review on AMT-260 for mesial temporal lobe epilepsy signifies progress in the company’s clinical pipeline, emphasizing potential for future revenue generation as it expands its therapeutic offerings.
Bears say
UniQure NV faces a negative outlook primarily due to the prospect of significant delays in its Biologics License Application (BLA) submission for AMT-130, as management has withdrawn prior guidance for a submission in the first quarter of 2026. The company's lack of commercially available products and ongoing financial losses since its inception heighten the financial risks associated with its clinical development stage. Additionally, increased market competition from existing and emerging therapies for similar indications poses a further threat to uniQure’s potential market penetration and pricing power.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares